Targeted anti-IL-13 therapies in asthma: current data and future perspectives
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2018.1427729
Abstract: ABSTRACT Introduction: The identification of patients with severe asthma who will benefit from a personalized management approach remains an unmet need. Interleukin-13 (IL-13) is a cytokine possessing a significant role in asthma pathogenesis and progression… read more here.
Keywords: targeted anti; therapies asthma; severe asthma; asthma current ... See more keywords
Utilization of exosome-based therapies to augment anti-PD-1/PD-L1 therapies
Sign Up to like & getrecommendations! Published in 2025 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2024-010603
Abstract: Abstract The development of immune checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway has significantly transformed the landscape of cancer treatment. However, resistance mechanisms such as alternative immune… read more here.
Keywords: anti therapies; therapies augment; exosome based; based therapies ... See more keywords
Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study
Sign Up to like & getrecommendations! Published in 2025 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2024-011184
Abstract: Anti-programmed death (ligand) 1 (anti-PD-(L)1) therapies were first introduced in the metastatic setting and have since been approved and reimbursed for treating early-stage cancers in the adjuvant, perioperative, and neoadjuvant settings in many cancer types.… read more here.
Keywords: stage cancers; treatment; anti therapies; early stage ... See more keywords
Treatment-related adverse events of PD-1 versus PD-L1 inhibitors commonly used in lung cancer therapy: Analysis of real-world FAERS data.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e14598
Abstract: e14598 Background: With the increasing utilization of immune checkpoint inhibitors (ICIs) in the dynamic landscape of cancer treatment, understanding immune-related adverse events (AEs) has become crucial for optimizing patient outcomes and therapeutic selection. In this… read more here.
Keywords: cancer; anti therapies; ror; ror 0001 ... See more keywords
First-in-human study of AWT020, a bifunctional anti-PD-1/IL-2 fusion protein, in patients with advanced cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e14500
Abstract: e14500 Background: Whileimmune checkpoint inhibitors have become the standard of care for multiple cancer types, resistance to anti-PD-(L)1 therapies remains a significant unmet medical need. AWT020 is a bifunctional fusion protein comprised of an anti-PD-1… read more here.
Keywords: fusion protein; anti therapies; resistance anti; awt020 bifunctional ... See more keywords
Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.966766
Abstract: Current treatments for central nervous system (CNS) inflammatory demyelinating diseases (IDDs) include corticosteroids, plasma exchange, intravenous immunoglobulin, and immunosuppressant drugs. However, some patients do not respond well to traditional therapies. In recent years, novel drugs,… read more here.
Keywords: central nervous; anti therapies; nervous system; demyelinating diseases ... See more keywords